Ganetespib in Combination with Pemetrexed-Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Carboplatin
/ administration & dosage
Cisplatin
/ administration & dosage
Female
Humans
Infusions, Intravenous
Injection Site Reaction
/ epidemiology
Male
Mesothelioma, Malignant
/ drug therapy
Middle Aged
Nausea
/ chemically induced
Pemetrexed
/ administration & dosage
Progression-Free Survival
Triazoles
/ administration & dosage
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 09 2020
15 09 2020
Historique:
received:
08
04
2020
revised:
02
06
2020
accepted:
09
07
2020
pubmed:
17
7
2020
medline:
15
12
2021
entrez:
17
7
2020
Statut:
ppublish
Résumé
Ganetespib, a highly potent, small-molecule Heatshock protein 90 inhibitor, has potential efficacy in malignant pleural mesothelioma (MPM) via activity on critical survival pathways and known synergies with antifolates and platinum chemotherapy. We conducted a dose-escalation study to identify the maximum tolerated dose (MTD) of ganetespib in patients with chemotherapy-naïve MPM. MESO-02 (ClinicalTrials.gov: NCT01590160) was a nonrandomized, multicenter, phase Ib trial of 3-weekly ganetespib (100 mg/m Of 27 patients enrolled (cisplatin, Ganetespib can be combined safely with pemetrexed and platinum chemotherapy to treat patients with MPM. This class of agent should be investigated in larger randomized studies.
Identifiants
pubmed: 32669375
pii: 1078-0432.CCR-20-1306
doi: 10.1158/1078-0432.CCR-20-1306
doi:
Substances chimiques
STA 9090
0
Triazoles
0
Pemetrexed
04Q9AIZ7NO
Carboplatin
BG3F62OND5
Cisplatin
Q20Q21Q62J
Banques de données
ClinicalTrials.gov
['NCT01590160']
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4748-4755Subventions
Organisme : Cancer Research UK
ID : 11402
Pays : United Kingdom
Informations de copyright
©2020 American Association for Cancer Research.